SIRNAOMICS-B (02257.HK): Establishes External Scientific Advisory Board with Five Renowned International Interdisciplinary Experts Onboard
NewTimeSpace News: SIRNAOMICS-B (02257.HK) announced the establishment of its External Scientific Advisory Board on 21 July 2026, consisting of five world-renowned interdisciplinary specialists covering RNA delivery technology, RNAi drug discovery, oncology R&D, translational clinical medicine, CMC operations and global pharmaceutical regulatory compliance. The panel will deliver independent, authoritative scientific guidance for the Group’s therapeutic pipeline programmes.
NewTimeSpace News: On 21 July 2026, SIRNAOMICS-B (02257.HK) released a voluntary announcement. The Company formally set up its External Scientific Advisory Board on the same date, staffed by five internationally distinguished cross-disciplinary experts to provide impartial and authoritative scientific counsel for all R&D projects within the therapeutic pipeline.
The five panel members are as follows:Dr. David Evans, Co-founder of the Company and core developer of the peptide nanoparticle delivery platform;Dr. Dmitry Samarsky, oligonucleotide therapy specialist and inventor of the GalAhead™ delivery platform;Dr. Johnson Yiu-Nam Lau, senior physician with extensive experience securing regulatory approvals from the FDA, EMA and TGA;Dr. Yi-Chao Hsieh, President of Arna Therapeutics, previously serving at Merck & Co. and Daiichi Sankyo, focusing on oncology research and development;Dr. Audrey Jia, former senior CMC reviewer at the FDA with profound expertise in regulatory strategies for IND, NDA and BLA filings.
The Group stated that the board members boast diversified industrial experience and global strategic vision. Their objective, independent professional insights will facilitate optimisation of the therapeutic pipeline and expansion of the Group’s global scientific research collaboration ecosystem.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
